Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zervimesine
- Development stage
- Phase 2
- Lead developer
- Cognition Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zervimesine is an investigational oral, once-daily small molecule drug being developed for the treatment of central nervous system (CNS) diseases such as Alzheimer's disease and dementia with Lewy bodies. It is also under investigation for dry age-related macular degeneration (AMD), particularly geographic atrophy. Zervimesine acts as a neuroprotective agent by preventing the binding of toxic oligomers—such as amyloid beta (Aβ) and alpha-synuclein—to neurons and synapses, thereby shielding them from damage. Its mechanism involves interaction with the sigma-2 receptor, which regulates pathways impaired in neurodegenerative diseases. The drug is being developed by Cognition Therapeutics[1][5][6][7].
- Brand names
- Elaytazervimesine
- Other names
- zervimesineCT1812CT-1812CT 1812
02
Targets
TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))
Beyond the preview
Go deeper on zervimesine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zervimesine.